Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Contract Development and Manufacturing Organization (CDMO) Market Outlook

The global contract development and manufacturing organization (CDMO) market size was valued at USD 225.58 billion in 2023, driven by rising demand for novel drugs and therapies to treat chronic diseases across the globe. The market is expected to grow at a CAGR of 9.1% during the forecast period of 2024-2032, with the values likely to rise from USD 244.53 billion in 2024 to USD 489.99 billion by 2032.

 

Global Contract Development and Manufacturing Organization (CDMO) Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 
Global Contract Development and Manufacturing Organization (CDMO) Market Overview

Contract development and manufacturing organization (CDMO) refers to an organization that partners with pharmaceutical companies to provide drug development and manufacturing services on a contractual basis. CDMO can help these firms outsource the manufacturing of drugs as well as assist in the development activities involved before the manufacturing process. Partnering with a CDMO offers multiple benefits to the pharmaceutical company such as reduced infrastructure costs, expertise from skilled staff, and necessary manufacturing capacity to increase production.

According to the data released by the World Health Organisation (WHO), chronic diseases or non-communicable diseases cause 41 million deaths every year, accounting for 74% of deaths globally. The prevalence of these chronic diseases, including cardiovascular diseases, cancer, and diabetes, responsible for increasing mortality rates, fuels the need for effective treatment options like novel drugs and therapies. Subsequently, this elevates the contract development and manufacturing organization (CDMO) market demand as more and more pharmaceutical companies are opting for such services to offer improved and efficient solutions to patients.

Increased Mergers and Acquisitions to Expedite Drug Development and Delivery

Contract development and manufacturing organizations (CDMOs) are increasingly engaging in mergers and acquisitions to keep up with changing customer requirements, which is a significant trend aiding market growth. In June 2023, KBI Biopharma, Inc., a cell line development CDMO, merged with Selexis SA, a global life sciences company, integrating as one organization under the name KBI Biopharma. This merger event will streamline drug development and manufacturing processes, including clinical and cGMP manufacturing services for mammalian programs.

Strategic partnerships can reduce manufacturing risks and accelerate the commercialization process of drugs by employing integrated resources and solutions. In January 2024, Kindeva Drug Delivery (a global CDMO specializing in drug-device combination products), announced the acquisition of Summit Biosciences Inc. (an intranasal drug delivery CDMO in the United States), to enhance its drug delivery capabilities and expand its biopharma customer base. The acquisition aims to offer improved intranasal drug delivery options in the coming years.

Strategic Investments Reinforce Contract Development and Manufacturing Organization (CDMO) Market Growth and Expansion

In July 2023, a leading biopharmaceuticals CDMO, Biovian announced its decision to invest EUR 50 million to facilitate the expansion of its manufacturing unit in Finland. The facility will be constructed in an area of 69,000 sq. ft, harboring advanced technologies to aid the development of Advanced Therapy Medical Products (ATMP), including adeno-associated viral therapies. The investment will help in increasing the production capacity of the company to align with the growing size of the CDMO market.

To meet the rising market demand, CDMOs are rapidly expanding their manufacturing capacities and capabilities to deliver optimal services to their customers at a larger scale. Strategic investments have enabled the leading CDMO players in the market to adapt to the changing landscape in the biopharmaceutical industry.

Global Contract Development and Manufacturing Organization (CDMO) Market By Service

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Contract Development and Manufacturing Organization (CDMO) Market Segmentation

Market Breakup by Service Type CMO

  • Active Pharmaceutical Ingredient (API) Manufacturing
    • Small Molecule
    • Large Molecule
    • High Potency (HPAPI)
  • Finished Dosage Formulation (FDF) Development and Manufacturing
    • Solid Dose Formulation
    • Liquid Dose Formulation
    • Injectable Dose Formulation
  • Secondary Packaging Services

Market Breakup by Research Phase CRO

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Market Breakup by Therapeutic Area

  • Oncological Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Contract Development and Manufacturing Organization (CDMO) Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Contract Development and Manufacturing Organization (CDMO) Market Regional Analysis

North America has been leading the contract development and manufacturing organization (CDMO) market during the historical period. This can be attributed to the presence of top CDMO players in the region who are constantly making investments and taking mergers and acquisitions initiatives to upscale their drug manufacturing capacities. In January 2023, a United States-based CDMO, Agilent Technologies reported a USD 725 million investment to double its manufacturing capacity. The investment was made to accommodate the surge in the therapeutic nucleic acids market and develop drugs targeting prevalent diseases like cancer and cardiovascular diseases.

Europe is another major market expected to hold a substantial contract development and manufacturing organization (CDMO) market share in the coming years. The robust medical infrastructure and advanced healthcare system drive the demand for novel drugs and vaccines to treat and prevent chronic diseases. Consequently, the major biopharmaceutical firms are working towards catering to the unmet medical needs of the patients.

Global Contract Development and Manufacturing Organization (CDMO) Market: Competitor Landscape

In January 2023, Lottee Biologics, a CDMO company headquartered in South Korea, announced its investment plan of USD 3 billion to build three mega plants, each with a production capacity of 360,000 liters by 2030. The company is expected to begin commercial production by 2027, aiming to generate USD 3 billion in revenue by 2034 and bolster the biopharma ecosystem, thereby accelerating the discovery of new therapeutics. The rising trend of internal investments by prominent biopharmaceutical companies is anticipated to increase the contract development and manufacturing organization (CDMO) market size in the forecast period.

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Catalant Inc.
  • Baxter Biopharma Solutions (Baxter International Inc.)
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • Recipharm AB
  • Albany Moleculer Research Inc. (AMRI)
  • Thermo Fisher Scientific
  • Boehringer Ingelheim Group
  • Pfizer Inc.
  • NextPharma Technologies
  • Jubilant Pharmova Ltd
  • Famar SA
  • Lonza Group
  • TapeMark
  • Novotech Pty Ltd
  • ARX LLC
  • Aenova Holding GmBH
  • Tesa Labtec GmbH (TESA SE)
  • CMIC Holdings Company Ltd
  • Syneos Health Inc.
  • LabCorp Drug Development

 Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report. 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Service Type
  • Research Phase
  • Therapeutic Area
  • Region
Breakup by Service Type
  • Active Pharmaceutical Ingredient (API) Manufacturing
  • Finished Dosage Formulation (FDF) Development and Manufacturing
Breakup by Research Phase
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Breakup by Therapeutic Area

  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Catalant Inc.
  • Baxter Biopharma Solutions (Baxter International Inc.)
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • Recipharma AB
  • Albany Moleculer Research Inc. (AMRI)
  • Thermo Fisher Scientific
  • Boehringer Ingelheim Group
  • Pfizer Inc.
  • NextPharma Technologies
  • Jubilant Pharmova Ltd
  • Famar SA
  • Lonza Group
  • TapeMark
  • Novotech Pty Ltd
  • ARX LLC
  • Aenova Holding GmBH
  • Tesa Labtec GmbH (TESA SE)
  • CMIC Holdings Company Ltd
  • Syneos Health Inc.
  • LabCorp Drug Development

Read Our Top Selling Reports

Latin America In-vitro Diagnostics Market

Latin America Advanced Wound Care Market

Global Aortic Valve Replacement Devices Market

Global Acute Kidney Injury Treatment Market

Global JE (Japanese Encephalitis) Vaccine Market

North America Laboratory Informatics Market

Global Laboratory Information System Market

South Africa Orthopaedic Braces and Supports Market

Health Economics and Outcomes Research (HEOR) Market

Picture Archiving and Communication System (PACS) Market

Contract Development and Manufacturing Organization (CDMO) Market Report Snapshots

Contract Development and Manufacturing Organization (CDMO) Market Size

Contract Development and Manufacturing Organization (CDMO) Market Regional Analysis

Contract Development and Manufacturing Organization (CDMO) Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market attained a value of about USD 225.58 billion in 2023, driven by the rising demand for novel drugs and therapies to treat chronic diseases across the globe.

The market is anticipated to grow at a CAGR of 9.1% during the forecast period of 2024-2032, likely to reach a market value of USD 489.99 billion by 2032.

The market demand is driven by the increase in the healthcare investments, disposable incomes, and the need for effective drugs to supplement the growth of the healthcare sector.

The increased mergers and acquisitions by prominent companies are one of the key market trends aiding the CDMO market growth. In January 2024, Kindeva Drug Delivery acquired Summit Biosciences Inc. to enhance its intranasal drug delivery capabilities.

The various services available in the market include active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, and secondary packaging services. Active pharmaceutical ingredient (API) manufacturing is further segmented into small molecule, large molecule, and high potency (HPAPI), whereas finished dosage formulation (FDF) development and manufacturing includes solid, liquid, and injectable dose formulation.

Based on the research phase CRO, the market is segmented into pre-clinical, phase I, phase II, phase III, and phase IV.

Based on the therapeutic area, the market is segmented into oncological, cardiovascular, and infectious diseases, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

Key players involved in the market are Catalant Inc., Baxter Biopharma Solutions (Baxter International Inc.), Vetter Pharma-Fertigung GmbH & Co. KG, Recipharm AB, Albany Moleculer Research Inc. (AMRI), Thermo Fisher Scientific, Boehringer Ingelheim Group, Pfizer Inc., NextPharma Technologies, Jubilant Pharmova Ltd, Famar SA, Lonza Group, TapeMark, Novotech Pty Ltd, ARX LLC, Aenova Holding GmBH, Tesa Labtec GmbH (TESA SE), CMIC Holdings Company Ltd, Syneos Health Inc., and LabCorp Drug Development.

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Pricing Plans

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Strategic Solutions for Informed Decision-Making

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-120-433-0800

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124